Cedars-Sinai
Technology &
Health Ventures

IMPACT REPORT

2026

Cedars Sinai

WELCOME

From Technology Transfer to Transformative Innovation

At Cedars-Sinai, our mission—to deliver exceptional care enhanced by research and education—demands continuous innovation. What began as a traditional technology transfer office has evolved into a multifaceted enterprise designed to accelerate that innovation at every stage.

Today, Cedars-Sinai Technology & Health Ventures provides not only core technology transfer services, but also advanced financial and venture capabilities that help transform ideas into market-ready solutions. Our teams pursue opportunities beyond the scope of traditional models—forming creative partnerships across the United States and internationally, and identifying pathways for innovations that might otherwise remain in the lab. Discoveries that once risked stalling now have the support, strategy and capital required to move forward as new treatments, diagnostics and tools for patient care.

This integrated approach brings together three complementary strengths: translating discoveries into real-world applications, advancing early-stage ideas through structured venture-building, and investing in high-potential companies positioned for scale. Engaging innovators across the full spectrum—from early insight to clinical adoption—helps us maximize the potential for meaningful impact.

Our evolution reflects a deliberate shift: from managing intellectual property to actively shaping the future of healthcare. By aligning scientific discovery with clinical insight and market strategy, we are better positioned to move promising ideas forward—faster, and with greater impact.

Our work remains tightly connected to the Cedars-Sinai mission. Every partnership we form and every innovation we advance is grounded in a single objective: improving patient outcomes. As we look ahead, we remain committed to accelerating ideas that matter—ensuring more breakthroughs reach the patients and communities who need them most.



JAMES D. LAUR, JD
Senior Vice President,
Intellectual Property and
Health Ventures

DAVID M. WRIGLEY
Executive Vice President
and Chief Financial Officer,
Cedars-Sinai Health System

IMPACT REPORT 2026

CONTENTS

PORTFOLIO INNOVATIONS

TECHNOLOGY VENTURES (Biotech, Medtech, Early Stage, LP)

HEALTH VENTURES (Health Tech, Series A)

Invention
Patent
Product Conception
Initial Validation
Company Formation
Secure Early Funding
Initial Product Development
MVP Release
Testing with Early Users
User Feedback
More Testing
Iterate Based on Feedback
Pivot if Necessary
Secure Additional Funding
Grow Customer Base
Expand Team
Add New Partners and Channels
Enter New Markets
Grow and Repeat

IDEATION → CREATION → VALIDATION → ITERATION → SCALE → EXPANSION

Cedars-Sinai Technology Ventures

SUPPORT FOR:

Very early companies exploring a product idea or building the first version of a product, as well as new technologies that need a core team and initial funding. Many internal innovation initiatives at Cedars-Sinai fit into this category.

WHAT WE DO:

- Provide commercial assessment and technical support for product development
- Initial investment or connection to pre-seed/seed venture investors
- Guidance on defining mission, overall strategy, and key milestones

Cedars-Sinai Accelerator+

SUPPORT FOR:

Companies that have developed an initial product and are ready to enter the B2B market. The founding team is in place and has typically raised some seed funding to support the product launch. The company often has a small number of early customers.

WHAT WE DO:

- Provide stakeholder feedback on product/market fit and business case
- Give access to a broad user base to drive product improvement and iteration
- Give guidance on sales process and cycle
- Refine messaging on value proposition to resonate with target customers

Cedars-Sinai Health Ventures

SUPPORT FOR:

Companies which have already raised a significant amount of funding but are looking to scale their product or to target larger customers. These companies typically have initial market validation. Cedars-Sinai is a key customer.

WHAT WE DO:

- Provide clinical and stakeholder feedback on product, business case and messaging
- Invest primarily in Series A and B rounds
- Make introductions to other health system customers and to an established network of venture firms

PORTFOLIO INNOVATIONS

Cedars-Sinai's unique innovation ecosystem translates discovery into real-world impact, delivering high-quality care for all with equity and compassion. Our investments advance patient care, accelerate research and strengthen communities worldwide, moving breakthrough therapies, medical devices and digital health solutions from the lab to clinical and commercial settings—and improving outcomes for patients far beyond Cedars-Sinai's campuses.

The global impact of this work helps shape standards of care, fuels new industries and reinvests resources into research and education, creating a virtuous cycle that benefits patients, clinicians and communities across the world.

As it transforms biomedical discoveries and innovations, our portfolio also generates income that is reinvested directly into Cedars-Sinai's mission, reinforcing a sustainable cycle of innovation and impact. These returns help support ongoing research, clinical excellence, community health and education—fueling new discoveries, advancing patient care and strengthening the academic and clinical environment that makes future breakthroughs possible. By reinvesting innovation-driven revenue back into the institution, Cedars-Sinai ensures that success in the marketplace translates into lasting benefit for patients, clinicians and the communities we serve.

Changing Lives

Collectively, companies within our portfolio have helped improve care for countless individuals—reaching patients through a range of clinical, operational and integrated health solutions.

Creating Jobs

Many of the companies we partner with concentrate on equipping clinicians and care teams, reinforcing the workforce capacity required to meet growing demand for healthcare services. These innovations are creating jobs around the globe.

Improving Efficiency

In parallel, technology-enabled solutions are accelerating diagnosis and clinical decision-making, helping clinicians identify disease earlier and begin appropriate treatment sooner. These advances reduce delays in care, improving e" ciency and supporting more timely, effective clinical interventions.

Spotlight

The Frykman-Kimble Stimulator is a low-cost, effective pediatric surgical nerve stimulator developed at Cedars-Sinai by Drs. Philip Frykman and Keith Kimble to treat children with life-threatening anorectal malformations (ARM).

Cedars-Sinai Technology Ventures provided key support and indispensable resources to develop the technology.
The device has since enabled local surgeons to perform surgery on tens of thousands of children who would have otherwise gone without.

REAL-WORLD IMPACT

278
Treatments or Drugs Advanced

Across the portfolio, 278 treatments and drug programs are moving forward with a clear focus on patients—bringing new and improved treatment options closer to the people who need them most. These efforts address diseases with few effective therapies today, offering the potential for better outcomes, fewer side effects and an improved quality of life.

161
Diagnostics or Tests Developed

Portfolio companies are strengthening the ability to detect disease earlier and more accurately with 161 diagnostics and tests developed or in use. These tools support prevention and early intervention by helping clinicians identify risk, confirm diagnoses sooner and guide timely treatment—often before conditions become more complex or costly to manage.

70
Research Tools Accelerating Translation

The portfolio also includes 70 research tools that help bridge the gap between discovery and patient care. By streamlining experimentation, validation and data analysis, these tools accelerate the transition from laboratory findings to clinical application—shortening timelines and enabling researchers to deliver real-world impact more e“ ciently.

106
Medical Devices Brought to Market

Portfolio efforts extend into device development, where emerging therapies advance toward clinical use with the potential to address unmet medical needs and improve outcomes for patients worldwide. These new devices were brought to market, addressing diseases that affect millions of people worldwide.

151
Digital or Software Solutions Deployed

The portfolio includes 151 digital and software-based solutions designed to support healthcare providers and care teams. These technologies improve clinical workflows, decision-making and system integration, reducing administrative burden, enhancing e“ ciency and allowing clinicians to spend more time focused on patient care.

9
Countries Served

Through a growing global footprint, portfolio companies extend beyond a single region, supporting care delivery, clinical research and operational innovation in nine countries. Their presence demonstrates scalability across diverse healthcare systems, expands access to diagnostics and treatments, and strengthens collaboration with research institutions and industry partners worldwide.

Spotlight

Under the leadership of Eduardo Marbán, MD, PhD, Cedars-Sinai advanced the development of cardiosphere-derived cells (CDCs), an off-the-shelf therapy designed to reduce inflammation, repair tissue and improve function in serious disease. Originally developed by Marbán at Johns Hopkins University, the technology and additional intellectual property are licensed to Capricor Therapeutics for clinical and commercial development.

STRATEGY

Cedars-Sinai's investment strategy is built on the foundation of advancing healthcare innovation

while maintaining alignment with our health system's mission. Across both of our investment arms, we prioritize partnerships with founders who demonstrate exceptional execution capabilities and a deep understanding of the healthcare landscape.

Technology Ventures and Health Ventures seek companies that o˝er breakthrough solutions with strong founder-market fit and clear strategic alignment with Cedars-Sinai, either today or in the future. Given the critical nature of healthcare innovation, we value founders who understand sustainable growth, positive unit economics, and the unique challenges of bringing healthcare solutions to market. We look for visionary leaders who can execute on their bold ideas in a targeted, disciplined manner.

We evaluate potential investments based on four core criteria:

- Strategic fit with Cedars-Sinai either today or in the future
- First-in-class, best-in-class, breakthrough solutions
- Strong founder market fit
- Revenue and market traction, as well as growth potential

Portfolio Value FY 2026 (INCLUDING EXITS)

$1.14 billion

To execute on this investment philosophy, we operate through two complementary investment arms, each tailored to specific stages and sectors within the healthcare innovation ecosystem.

Cedars-Sinai Technology Ventures

(CSTV) supports early-stage healthcare and life science startups aligned with Cedars-Sinai's mission and where we can provide meaningful operational support.

Cedars-Sinai Health Ventures

(CSHV) is the strategic venture arm of Cedars-Sinai, investing primarily in Series A software, AI, HCIT, and tech-enabled services companies with clear product–market fit and strong strategic alignment.

Cedars-Sinai Accelerator+

supports the growth and development of early-stage companies focused on improving healthcare and healthcare delivery through mentorship, financial investment, and access to our health system. Startups receive support, with defined milestones and a curated curriculum including specialized workshops and sessions.

PORTFOLIO

VENTURE DEVELOPMENT

BUSINESS UNITS

VENTURE UNITS

WHOLLY OWNED

VENTURE CREATION

SELECTED PORTFOLIO COMPANIES

EXITED

LP INVESTMENTS

Our investment portfolio embraces the full spectrum of innovation in the healthcare space, from basic research to consumer-facing technology, including:

- MOLECULES
- PHARMACEUTICALS
- BIOTECHNOLOGY
- MEDICAL DEVICES
- ARTIFICIAL INTELLIGENCE/ MACHINE LEARNING
- GENOMICS/GENETICS DECISION SUPPORT
- DIGITAL HEALTH
- CARE DELIVERY MODELS
- CARE MANAGEMENT
- SUPPLY CHAIN MANAGEMENT
- REVENUE CYCLE
- CYBERSECURITY
- BUSINESS/ ADMINISTRATIVE SOLUTIONS
- WELLNESS AND FITNESS APPS
- PHRS/PERSONAL HEALTH MANAGEMENT

Why Cedars-Sinai?

With 1.85 million outpatient visits, 50,000 admissions and 125,000 emergency visits annually, Cedars-Sinai has the patient volume and clinical complexity to identify meaningful programs, pilot new solutions and validate innovations in real-world settings.

TECHNOLOGY VENTURES

Cedars-Sinai Technology Ventures (CSTV) is the early-stage investment arm of Cedars-Sinai, focused on healthcare and life science startups across med tech (devices and diagnostics), biotech (drug discovery programs) and health tech (regulated digital health). CSTV typically invests in companies at the pre-commercialization stage that align with Cedars-Sinai's mission to advance healthcare and improve patient outcomes.

Our focus is on companies in which we can provide operational support across regulatory pathways, pricing strategies, reimbursement planning, pilots and enterprise-wide contracts. With more than $230 million invested in the portfolio to date, we invest o˝ the balance sheet of Cedars-Sinai Health System. We don't require revenue traction pre-investment but look for strong founder-market fit and breakthrough technology potential. We can lead, co-lead or follow in rounds, maintaining long-term commitments until companies achieve their intended outcomes.

"The journey from laboratory breakthrough to bedside impact is complex, with challenges that capital alone cannot solve. Our approach goes beyond investment. We partner with early-stage innovators to provide the clinical expertise and strategic infrastructure needed to advance development and deliver meaningful impact for patients."

NIRDESH GUPTA, PhD
Managing Partner, Cedars-Sinai Technology Ventures

FINANCIAL SNAPSHOT

$142 million

in licensing revenue in the last 5 years

Projected similar licensing income through 2030

30% of portfolio

is licensed or optioned

Companies by Sector

As a nonprofit institution, Cedars-Sinai reinvests the revenue generated through intellectual property into the health system to help advance research, innovation and future discovery.

CASE STUDY

$10.8 billion
VALUE AT EXIT

Prometheus's $10.8 billion acquisition by Merck was among the largest biotech deals of 2023, validating the precision IBD space commercially. Cedars-Sinai's nearly $800 million return demonstrated that startup companies from academic medical centers that have been derisked before spinning out can generate transformative financial outcomes.

$40 million
INVESTED

PROMETHEUS BIOSCIENCES

Focus Area	**Therapeutics for IBD**
Category	**Precision Medicine**
Opportunity	**The global IBD treatment market is valued at $22.3 billion.**

Prometheus Biosciences is a clinical-stage biotechnology company specializing in precision medicine for immune-mediated diseases, particularly inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease. Utilizing their proprietary Prometheus360 platform, the company combines machine learning-based analytics with extensive gastrointestinal bioinformatics to identify novel therapeutic targets. **In 2023, Merck acquired Prometheus Biosciences for approximately $10.8 billion.**

Cedars-Sinai Involvement

Prometheus Therapeutics was built on intellectual property exclusively licensed from Cedars-Sinai, rooted in more than two decades of research led by Dr. Stephan Targan, Dr. Dermot McGovern and the institution's IBD biobank. Cedars-Sinai remained deeply engaged as a strategic investor, with board representation and ongoing scientific collaboration that helped guide the company's development.

Unique Value

- Combines machine learning-based analytics with the world's largest IBD biobank.

Early Wins

- Positive clinical trial results were shown across multiple antibody treatment candidates.
- PRA023, a TL1A-targeting antibody, received FDA IND acceptance in late 2020, triggering rapid development for ulcerative colitis and Crohn's disease.

Social Impact

- Moved treatment from trial-and-error toward precision medicine, offering new hope for remission among patients.

Financial Impact

- Analysts project the TL1A antibody class could generate billions in annual revenue.

"Anti-TL1A therapy is a very promising mechanism for the treatment of IBD, and everyone has been waiting for companion diagnostic directed therapy that will allow us to treat the right patient with the right drug."

William Sandborn, MD
Chief of Gastroenterology and Director, IBD Center, UC San Diego
External clinical investigator, Prometheus ARTEMIS-UC Trial

CASE STUDY

GRAVIDAS DIAGNOSTICS

Focus Area	**Preeclampsia Diagnostic**
Category	**Women's Health**
Opportunity	**Preeclampsia impacts 5–8% of all pregnancies in the U.S. resulting in 200,000 cases per year.**

Gravidas Diagnostics' rapid point-of-care (POC) test is designed to improve pregnancy outcomes. The assay identifies individuals at risk for severe preeclampsia— **a condition affecting approximately 5–8% of pregnancies in the United States** —addressing a critical unmet need and with the potential to reduce maternal and fetal morbidity and mortality worldwide.

The Gravidas test could reduce reliance on a battery of tests, including blood pressure measurement, urine protein testing, blood chemistry panels and clinical assessment of maternal symptoms.

Cedars-Sinai Involvement

Gravidas was spun out of Cedars-Sinai Medical Center based on licensed technology developed through research led by Drs. Ravi Thadhani, Anders Berg and Ananth Karumanchi, whose multicenter study supported FDA approval of a blood test for preeclampsia. Cedars-Sinai continues to support the company through its intellectual property arm and ongoing research collaboration.

Unique Value

* **Low-cost, rapid and usable at home, it enables proactive intervention before life-threatening symptoms develop.**

Early Wins

* **In 2024, Gravidas Diagnostics was awarded a $3 million federal grant from ARPA-H.**
* **Gravidas Diagnostics is working toward submitting a 510(k) application to the FDA to bring its test to market.**

Social Impact

* **An affordable, at-home test could democratize early detection, reduce racial disparities and reach women in communities who lack regular obstetric access.**

Financial Impact

* **Early preeclampsia intervention reduces costly emergency hospitalizations, ICU admissions and NICU stays.**

> **"Pregnant women with risk factors and limited access to routine obstetric care will be the largest beneficiaries of this home-based test."**
>
> **Sarah J. Kilpatrick, MD, PhD**
> Chair, Department of Obstetrics and Gynecology
> Cedars-Sinai

CASE STUDY



JUPITER BIOVENTURES

Focus Area	**Drug Development**
Category	**Precision Medicine**
Opportunity	**The "science first, fail fast" model aims to reduce the time and cost of getting novel therapeutics to patients.**

Jupiter Bioventures is a biotech venture-foundry deploying a "science first" model in which it evaluates promising scientific ideas, or "Moons," de-risks them through early-stage seed investments and experimentation, and **scales the most promising ones into fully independent therapeutic companies**. Jupiter brings together scientists, entrepreneurs and investors under one collaborative model.

Cedars-Sinai Involvement

Cedars-Sinai Technology Ventures is a co-founding investor in Jupiter's $70 million inaugural fund. Cedars-Sinai holds a seat on the board.

Unique Value

- **Vertical integration: Company development, capital infusion, and scientific incubation all exist under one roof.**

Early Wins

- **The company raised an initial $70 million from a strong syndicate of biotech investors.**
- **Successfully validated its first "Moon" concepts through preclinical proof-of-concept studies.**

Social Impact

- **This approach has the potential to generate multiple new medicines for cancer and diseases where cancer biology provides insight, particularly conditions with significant unmet need and large patient populations.**

Financial Impact

- **The foundry model is designed to achieve higher capital e©ciency than traditional venture models by de-risking early and scaling only validated science.**

> **"Mayo Clinic is committed to producing meaningful, effective change that transforms health and medicine. Clinical excellence requires continual discovery, translation and innovation. We're eager to see what innovations show promise through this unique biotech model."**

Vijay Shah, MD
Kinney Executive Dean for Research, Mayo Clinic
Co-founding investor in Jupiter Bioventures

CASE STUDY

MITERA BIOSCIENCES

Focus Area	**Autoimmune disorders; Transplant rejection**
Category	**Therapeutic Development**
Opportunity	**Developing safer and more effective therapeutics derived from our innate immune system.**



Mitera Biosciences is developing groundbreaking investigational therapeutics with **a novel mechanism of action leveraging three key features:** (1) impairment of effector T cells (Teffs); (2) proliferation of regulatory T cells (Tregs); and (3) downregulation of B cell activation, proliferation, and antibody production. This combination of attributes is highly unique and could provide effective and well tolerated therapeutics for patients in need, if successful in future clinical studies.

Cedars-Sinai Involvement

Mitera was founded on intellectual property exclusively licensed from Cedars-Sinai, which also provided initial seed funding. Co-founder Dr. Stanley Jordan serves as Director of the Kidney Transplant Program at Cedars-Sinai. Co-founder Dr. Ananth Karumanchi conducts research at Cedars-Sinai as a collaborator.

Unique Value

- **Mitera's approach could enable lasting immune tolerance rather than blunt systemic suppression.**

Early Wins

- **The company raised a $2 million seed SAFE financing including over $1 million from Cedars-Sinai Health Ventures.**

Social Impact

- **Current immunosuppressants require lifetime monitoring and cause serious side effects. Mitera's natural-protein approach could dramatically improve quality of life for transplant recipients and autoimmune patients.**

Financial Impact

- **Autoimmune diseases and organ transplant rejection cost over $100 billion annually in U.S. care.**

> **"The biology underlying Mitera's pursuit is really new. While there's clear potential for treating transplant patients, the therapy could be used for so many bigger, broader diseases out there, and that's really exciting."**

Kevin Chow, PhD
Co-founder, President and CEO, Mitera Biosciences

CASE STUDY

GEMELLI BIOTECH

Focus Area	**Gastrointestinal disease**
Category	**Precision Diagnostics**
Opportunity	**IBS affects ~800 million people globally and ~35 million in the U.S.**

Gemelli Biotech is a precision diagnostics company focused on advancing the understanding and diagnosis of functional GI disorders. Founded out of research from Cedars-Sinai, the company develops non-invasive tests that measure key biomarkers to **provide clearer insights into conditions like IBS and SIBO**. Gemelli aims to improve patient outcomes and reduce costs for clinicians and payers.

Cedars-Sinai Involvement

Both ibs-smart® and trio-smart® were developed in partnership with Cedars-Sinai's MAST (Medically Associated Science and Technology) program. Dr. Mark Pimentel, a co-founder and scientific advisor, helped lead a 2,500-patient study at Cedars-Sinai from which the tests emerged. Cedars-Sinai has participated in funding rounds.

Trio-Smart® measures the levels of hydrogen, methane and hydrogen sulfide to provide you with a more complete picture of gut health.



Unique Value

- **Gemelli transformed how IBS is diagnosed with tests that address a 40 to 60% misdiagnosis rate in functional GI disorders.**

Early Wins

- **The company launched its first diagnostic, ibs-smart®, a blood test that helps move IBS diagnosis from exclusion to causality.**
- **Its second test, trio-smart®, is a breath test designed to provide a fuller picture of gut microbiome gases.**

Social Impact

- **Patients get faster diagnoses and targeted treatment—especially women, who are often overlooked despite being disproportionately affected by IBS.**

Financial Impact

- **With IBS costing the U.S. healthcare system billions annually, precision diagnostics represent major cost savings for payers, patients and providers.**

> "I'm just very thankful for it because I am starting to feel better for the first time in over five years."

Sarah
IBS patient using Gemelli Biotech's diagnostic testing

ACCELERATOR+

Nothing is worse for a mid-stage company than a premature 'no.'

The Cedars-Sinai Accelerator+ program allows clinicians from the Cedars-Sinai Health System and key opinion leaders to engage, providing feedback and guidance. The program represents the evolution of our proven accelerator model into a comprehensive venture-building platform for Seed+ and Late Seed healthcare companies advancing toward commercialization. We partner directly with startup teams, providing capital investment, clinical and market expertise and guaranteed fast-track evaluation for product development within the Health System and beyond, by providing qualified connections into a national network of academic medical centers who are looking to implement new solutions in their institutions. Our rolling program delivers real-world validation, streamlines clinical integration, and provides strategic guidance to scale innovation and, ultimately, improve patient outcomes.

"Every startup faces its own mix of funding, clinical and infrastructure challenges on the road to commercialization and addressing unmet patient needs. Our role is to partner with them and provide bespoke guidance throughout their journey at Cedars-Sinai and across the broader U.S. healthcare system."

KINSHUK KOCHER, MBA
Director, Venture Investing,
Cedars-Sinai Technology Ventures

KEVIN WINSTON
Director, Business Development and Programs,
Cedars-Sinai Technology Ventures

CASE STUDY

SYNTHO.AI

Focus Area	**Data Privacy and Protection**
Category	**Data, Synthetic Data**
Opportunity	**Data initiatives require secure access to data, which demands significant time and resources.**

Syntho.ai is an Amsterdam-based company revolutionizing the tech industry with AI-generated synthetic data. As the leading provider of synthetic data software, Syntho's mission is to empower businesses worldwide to **generate and leverage high-quality synthetic data at scale**.

Synthetic data can simulate a wide variety of edge cases and real-world scenarios early in development, helping to identify bugs and issues before they escalate.



Cedars-Sinai Involvement

Syntho participated in the Cedars-Sinai Accelerator and subsequently completed a pilot with Cedars-Sinai. The institution specifically cited Syntho as a tool to lower barriers for clinical researchers, speed up study launch and sunset, and enable students to use synthetic data for learning—goals now integrated into Cedars-Sinai's Digital Innovation Platform strategy.

Unique Value

- **Syntho enables researchers and developers to work with realistic datasets without the months-long approval processes associated with real patient data, thus removing a critical bottleneck in healthcare AI development.**

Early Wins

- **Winner, Philips Innovation Award.**
- **Winner, NL Startup Competition.**
- **Winner, Global SAS Hackathon.**

Social Impact

- **Syntho democratizes data access for researchers, startups and trainees. Broader, faster AI development means better clinical tools reaching patients sooner.**

Financial Impact

- **A single Syntho deployment can save over $10,000 per research project by compressing timelines from years to months.**

> **"The use of synthetic data reflects our pursuit of cutting-edge technologies to advance medical research and improve patient care."**

Craig Kwiatkowski, PharmD
Senior Vice President and Chief Information Officer, Cedars-Sinai

CASE STUDY

AEVICE HEALTH

Focus Area	**Respiratory Care**
Category	**Device and Digital Health**
Opportunity	**Early detection of chronic respiratory diseases could benefit more than 500 million people.**

Aevice Health's flagship product, the AeviceMD, is **the world's smallest smart wearable stethoscope, designed for continuous, non-invasive monitoring of lung sounds at home**. AeviceMD enables patients, including children and adults, to receive hospital-quality respiratory insights from home.

Cedars-Sinai Involvement

Aevice Health participated in the Cedars-Sinai Accelerator, where it refined its U.S. product-market fit and product launch strategy with guidance from Cedars-Sinai clinical leaders and hospital administrators. Cedars-Sinai Medical Center is both an investor and a deployment site for the AeviceMD device.

Paired with the AeviceMD wearable stethoscope, the AeviceMD app delivers actionable insights into patients' asthma or COPD status, enabling more informed and proactive disease management.



Unique Value

* **Detects wheezing, tracks respiratory and heart rate, and alerts clinicians to early deterioration—enabling proactive intervention before hospitalization becomes necessary.**

Early Wins

* **Secured two U.S. FDA clearances.**
* **CES Innovation Awards 2023– Best of Innovation in Digital Health.**
* **Digital Health Awards 2023 Quarter-finalist: Best in Class for Pediatric-Adolescent Care Innovation.**

Social Impact

* **Home-based monitoring allows patients to avoid unnecessary ER visits, receive timely adjustments to their care plan and maintain independence.**

Financial Impact

* **For a cohort of 5,000 patients, a 10% reduction in hospitalizations could reduce acute care costs by more than $5 million per year.**

"We are on a mission to bring the same level of care from the hospital straight into patients' homes, empowering them to achieve better control over their conditions."

Adrian Ang
CEO and co-founder,
Aevice Health

CASE STUDY

3 hours
Average daily staff time saved per team member

1,500
Additional new patients as a result of increased capacity

$4.1B
Healthcare spend directed to high-quality care

AIDIN

Focus Area	**Post-acute care**
Category	**Care Coordination and Revenue Cycle**
Opportunity	**Post-acute care costs the U.S. health system $45 billion per year.**

Aidin is a care coordination platform that **empowers patients and hospitals to make data-driven decisions during discharge planning.** Its marketplace model introduces transparency and performance metrics into the traditionally opaque post-acute care referral process.

Cedars-Sinai Involvement

Aidin is part of the Cedars-Sinai Accelerator portfolio, with commercialization support and ongoing investment from Cedars-Sinai Health Ventures. The partnership has supported deployment across leading health systems, including UCLA Health, Vanderbilt Health, Mount Sinai Health System and Yale New Haven Health, leveraging Cedars-Sinai's network and credibility.

Unique Value

* **Enables performance-based referrals integrated with major EMRs such as Epic that align hospital incentives with patient outcomes.**

Early Wins

* **Deployed in leading health systems such as Mount Sinai and Yale New Haven Health.**

Social Impact

* **A reduction in readmissions by more than 20% directly impacts patient quality of life.**

Financial Impact

* **Delivered nearly $8 million in cost savings at St. Luke's University Health Network in a single year.**
* **A one-third day reduction in average length of stay per implemented patient adds thousands of available bed-days per year.**

"Aidin's platform will allow us to standardize workflows to reduce administrative burden and decrease variability in care transitions across the continuum of care."

Jeannine Nylaan, MSN, RN
Executive Director of Care Management, AdventHealth

CASE STUDY



The Kneu Health app includes home-based tests that measure balance, walking, dexterity, tremor, reaction time and voice.

KNEU HEALTH

Focus Area	**Parkinson's and Dementia**
Category	**Digital Health (SaMD)**
Opportunity	**Makes earlier intervention and personalized care possible without requiring new hardware.**

Kneu Health is a spinout from the University of Oxford and is pioneering smartphone-based solutions to transform Parkinson's Disease and dementia. **Its platform turns everyday smartphones into FDA-registered, certified medical devices** using proprietary biomarkers and AI-powered analytics.

Cedars-Sinai Involvement

Cedars-Sinai co-led Kneu Health's $5.6 million seed round alongside Oxford Science Enterprises. Kneu Health is deployed at Cedars-Sinai as part of a validated clinical pilot, where it demonstrated 30% e©ciency gains in neurology clinics.

Unique Value

* **Kneu Health's platform transforms everyday smartphone interactions into clinical intelligence.**

Early Wins

* **Recipient of the 2024 NHS H&J National Award for Digitizing Patient Care.**
* **Secured contracts with NHS hospitals in the UK and finalizing pilot agreements with three leading U.S. healthcare systems.**

Social Impact

* **Reduced emergency admissions for Parkinson's patients by 1.2% compared to a 9% national increase (UK) during the same period.**

Financial Impact

* **Generates $3,000 in savings per patient per year through reduced emergency visits and hospitalizations.**

> **"This is a really interesting opportunity to move monitoring and care for a chronic condition like Parkinson's out of the hospital clinic and into people's homes."**

Dr. Andrew Graham
Consultant Neurologist, Oxford Health NHS Foundation Trust, a Kneu Health clinical deployment partner

CASE STUDY

HEALTHLEAP

Focus Area	**Malnutrition**
Category	**Clinical SaaS**
Opportunity	**One in three hospital patients in the U.S. suffer from malnutrition, yet only 6% are diagnosed.**

88% **higher sensitivity** **than nurse-administered malnutrition screening**

HealthLeap's NutriLeap is an AI-powered clinical nutrition decision support app that helps dietitians automate medical calculations and **provides data-driven recommendations for improving patient nutrition care**. The solution aims to reduce hospital malnutrition by streamlining clinical workflows and enhancing the quality of care for patients.

Cedars-Sinai Involvement

NutriLeap was deployed at Cedars-Sinai as a commercial implementation. A validation study was co-authored by researchers at Cedars-Sinai, Johns Hopkins, and Stanford Health. HealthLeap also received commercialization support and continued investment from Cedars-Sinai, which is listed among its innovation partners.

Unique Value

- **Unlike nurse-administered screening tools, NutriLeap analyzes medical history, body measurements, lab results and symptoms to flag subtle at-risk patients.**

Early Wins

- **At Cedars-Sinai, 39% more malnutrition cases were diagnosed using the software with a one- to two-day shorter length of stay.**

Social Impact

- **Enables the identification of a significant number of malnutrition cases that are unidentified using traditional screening methods.**

Financial Impact

- **Generated over $9 million in single-site revenue savings and $10.5 million in total annual financial impact at Cedars-Sinai alone.**

> **"AI tools that continuously screen patient records and surface risk in real time are exactly the kind of clinical decision support dietitians need."**

Peer-reviewed validation study co-authored by researchers at Cedars-Sinai, Johns Hopkins and Stanford Health—published in support of NutriLeap's AI model (AUROC 0.92 on Day 1 hospitalization data)

Why Cedars-Sinai?

Cedars-Sinai's world-class research enterprise drives a continuous pipeline of discovery, translating scientific insight into practical applications. This depth of expertise enables rapid validation, strong clinical evidence and a steady flow of innovations ready for development, commercialization and real-world impact.

HEALTH VENTURES

Cedars-Sinai Health Ventures (CSHV) is the strategic venture arm of Cedars-Sinai. CSHV focuses on investments in software, AI, health information technology and tech-enabled services companies that have achieved product/market fit and share our mission to transform healthcare delivery. CSHV typically invests at Series A but can invest at Seed or Series B. We look for strategically and mission-aligned businesses where we can implement and deploy core product rapidly, enterprise-wide, then pursue further collaboration on product extension. A pilot or commercial agreement is not required pre-investment, but a clear line of sight to commercial engagement with key stakeholders is essential. CSHV maintains flexibility in deal structure.

> "By rapidly deploying these innovations enterprise-wide, we ensure that cutting-edge solutions reach our clinicians and patients quickly, delivering measurable impact where it matters most."

MAUREEN BURGESS, JD
Partner, Cedars-Sinai Health Ventures

CASE STUDY

AMAE HEALTH

Focus Area	Integrated severe mental illness (SMI) care
Category	Outpatient Care
Opportunity	Nearly 5% of U.S. adults live with SMI, yet less than half receive adequate treatment.

Amae Health is a value-based care provider focused on SMI, delivering psychiatry-led, long-term outpatient care through a multidisciplinary model that includes therapy, primary care and social support, while advancing research to transform outcomes and **set a new standard for SMI treatment across diverse communities nationwide.**

A New Standard for SMI Care

	Standard of Care	Amae Health
30-day ER readmissions	23%	4%
Average length of stay per readmission	15 days	1.5 days
Medication adherence	5.3%	90%
Engagement	70% dropout after 1–2 visits	7% dropout

Cedars-Sinai Involvement

Cedars-Sinai invested $6 million in Amae Health, building on a two-year partnership that began when the company opened its first Los Angeles clinic. The collaboration provides continued investment, clinical credibility, a strong referral ecosystem in Los Angeles and validation of Amae Health's model as a potential center of excellence for SMI care within the Cedars-Sinai network.

Unique Value

- The concept integrates psychiatry, primary care, therapy, health coaching, peer support, and social work in a single outpatient clinic.

Early Wins

- Four fully deployed clinics in Los Angeles, Raleigh, New York, and Los Altos, with additional sites anticipated over time.
- Signed value-based contracts with top payers, including Carelon, Alliance Health, BCBS, Aetna and Optum.

Social Impact

- Amae Health keeps patients engaged (7% dropout vs. 70% national average after 1 to 2 visits) through compassionate, consistent outpatient care.

Financial Impact

- A 4% 30-day readmission rate represents dramatic reductions in ER and inpatient spend—the most expensive care settings.

> “Amae is advancing a model of care that prioritizes clinical excellence and compassionate, patient-centered services. By combining an outstanding team of clinicians with a thoughtful approach to long-term care, Amae is delivering outcomes that are both significant and sustainable.”

Itai Danovitch, MD
Chairman, Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai

CASE STUDY

Rx REDEFINED

Focus Area	**Medical Supply Distribution**
Category	**Outpatient Care**
Opportunity	**A fragmented Durable Medical Equipment industry valued at over $600 billion leaves providers burdened with inefficiencies.**

Rx Redefined is a healthcare technology company that streamlines how patients receive recurring-use medical supplies by enabling physicians to distribute these supplies directly to their patients. Founded in 2018, the company **removes traditional intermediaries, improving patient experience, access and compliance** while unlocking a new revenue stream for providers.



Rx Redefined helps physicians distribute recurring-use medical supplies directly to patients, reducing delays and improving access to needed products.

Cedars-Sinai Involvement

Cedars-Sinai is a commercialization and investment partner for Rx Redefined. The platform's physician-centered model aligns with Cedars-Sinai's focus on integrated care delivery and reducing friction in patient-physician relationships.

Unique Value

- **The platform handles compliance, medical billing requirements and patient eligibility verification for every order.**

Early Wins

- **In the last year, Rx Redefined grew booked sales 10-fold and increased its physician population by 450%.**
- **To date, the platform has enabled physicians to distribute millions of medical products to their patients.**

Social Impact

- **Patient noncompliance with medical equipment drives preventable complications and readmissions. By keeping supply distribution within the physician's o©ce, Rx Redefined improves education, adherence and outcomes for patients.**

Financial Impact

- **The platform removes costly intermediaries, creating savings for payers while generating new revenue for physician practices.**

"When patients leave with the right product, properly fitted, and with instructions from a provider they already trust—rather than getting a box mailed to them weeks later—their compliance is dramatically better."

Physician partner
Rx Redefined platform

CASE STUDY

HEALTH NOTE

Focus Area	Patient Access
Category	Digital Health
Opportunity	Manual intake delays throughput, reduces patient satisfaction, and burdens clinical staff.

70% resolution rate without human transfer

80% reduction in average hold times

50% reduction in abandoned calls

Health Note is a clinician-founded AI platform for patient access across voice, text and web. Health Note's Access AI handles scheduling, refills and patient cases with frictionless, platform-agnostic integration into electronic medical records. By restoring meaningful clinical time, **Health Note helps physicians dedicate more attention to each patient interaction**.

Cedars-Sinai Involvement

Cedars-Sinai Health Ventures was an early investor in the company. Health Note is actively deployed throughout the Cedars-Sinai network.

Unique Value

* The clinical decision-tree approach is integrated into the electronic medical record rather than relying on traditional questionnaires which need to be input into the patient's medical record manually.

Early Wins

* Deployed across more than 300 clinical sites across the U.S.
* More than 500,000 patient interactions per month across voice, text and web.

Social Impact

* Thousands of hours of clinical staff time redirected from phones to in-person patient care.
* Expanded after-hours patient access without adding headcount

Financial Impact

* Rapid ROI, driven by lower labor costs, higher throughput and improved patient satisfaction.
* An 80% reduction in provider documentation time translates to direct, measurable FTE cost savings.

> "Health Note is solving one of the single biggest pain points in the healthcare system—the physician burnout epidemic."

Jill Kalman, MD
Senior Vice President and Chief Medical Officer, Northwell Health—
Health Note Series A investor and clinical deployment partner

CASE STUDY

REGARD

Focus Area	**AI Diagnostic Support**
Category	**Outpatient Care**
Opportunity	**A single patient record contains 50,000 data points on average, 97% of which goes unseen.**



Regard is an AI-powered clinical co-pilot that helps physicians diagnose conditions and generate documentation directly within the electronic medical record. By analyzing patient records, it surfaces potential missed diagnoses, streamlines clinical workflows and improves billing accuracy with the goal of **reducing administrative burden and helping hospitals support accurate revenue capture while enhancing patient care**.

Cedars-Sinai Involvement

Cedars-Sinai Health Ventures is an investor. Cedars-Sinai Medical Center and Cedars-Sinai Marina del Rey Hospital were among Regard's earliest major health system deployments.

Unique Value

- **The platform combines advanced AI with deep clinical understanding to automate complex medical coding with unmatched accuracy.**

Early Wins

- **Deployed in Cedars-Sinai, Banner Health, Sentara Health System, WakeMed Health and Hospitals, and more.**
- **Regard raised $61 million and signed 25 active commercial contracts.**

Social Impact

- **Physicians using Regard's system reported saving up to 10 minutes per patient after implementation.**

Financial Impact

- **Using Regard's platform has generated over $150 million in net new revenue for users.**

> **"Regard has been a game-changer, as it surfaces critical information that may have been missed, directly impacting patient care without adding extra work for doctors."**
>
> **David Kirk, MD**
> Chief Clinical Integration Officer, WakeMed Health and Hospitals

Why Cedars-Sinai?

A broad and diverse patient population provides rich clinical insight and real-world context. This diversity strengthens research relevance, supports inclusive study design and ensures innovations are developed, tested and refined to meet the needs of varied populations and care settings.

TEAM

DAVID M. WRIGLEY
Executive Vice President
and Chief Financial Officer,
Cedars-Sinai Health System

JAMES D. LAUR, JD
Senior Vice President,
Intellectual Property and
Health Ventures

NIRDESH K. GUPTA, PhD
Managing Partner,
Cedars-Sinai Intellectual
Property Company

MAUREEN BURGESS, JD
Executive Director,
Cedars-Sinai Health Ventures

To learn more about our team,
scan the QR code or visit
**cedars-sinai.edu/research/
technology-innovations/team.html**



JULIEN BROHAN, MS, CLP
Director, MedTech Ventures,
Cedars-Sinai Tech Ventures

ALEX CHAI, JD
Executive Director,
Tech Ventures Legal

WENYUE DU, PhD
Director, Biotech Ventures,
Cedars-Sinai Tech Ventures

KINSHUK KOCHER, MBA
Director, Venture Investing,
Cedars-Sinai Tech Ventures

PETER S. PARK, JD
Director, Business Operations,
Cedars-Sinai Tech Ventures

OMAR PEREZ
Manager, Portfolio Business Affairs,
Cedars-Sinai Accelerator+

ROHIT RAJKUMAR
Director, Business Development,
Cedars-Sinai Health Ventures

ERIC R. SEE
Executive Director,
Tech Ventures Operations

SAMANTHA SHOBASH
Manager, Program Operations,
Cedars-Sinai Accelerator+

COLIN TAN
Investment Director,
Coronet Ventures (Singapore)

KOEN VAN BREUGEL
Investment Director,
Coronet Ventures (Netherlands)

KEVIN WINSTON
Director, Business Development
and Programs,
Cedars-Sinai Tech Ventures

GLOBAL IMPACT

Cedars-Sinai Technology Ventures has been building international relationships for more than two decades, helping to identify and nurture promising biotechnology partners and bring innovative medical solutions to patients worldwide. Some of these relationships have evolved into significant partnerships and investments, extending our impact globally.

KEY INTERNATIONAL MARKETS

- **Singapore**
- **The Netherlands**
- **The United Kingdom**

18 portfolio companies

3 commercial contracts at Cedars-Sinai

13 strategic partnership initiatives

SINGAPORE

Agency for Science, Technology and Research SINGAPORE

CLAVYSTBIO

dxdhub DIAGNOSTICS DEVELOPMENT HUB

Enterprise Singapore

NHIC National Health Innovation Centre

sggrowth capital

THE UNITED KINGDOM

MERIDIAN HEALTH VENTURES

OXFORD SCIENCE ENTERPRISES

THE NETHERLANDS

ScaleNL

NBSO NL Los Angeles

Health~Holland

> "Our partnership with Cedars-Sinai helps promising UK healthcare startups take a critical leap into the U.S. market, pairing commercial and clinical insights with real-world opportunities to validate and refine their technologies."

Heather Roxborough
Senior Partner
Head of HealthTech
Oxford Science Enterprises

Grounded in a tradition of service and innovation, Cedars-Sinai Technology & Health Ventures drives forward with a clear purpose: to do well by doing good—working with our partners to advance discoveries that improve lives while honoring a legacy rooted in compassion, community and care.

Cedars Sinai